Recent developments include capital raising activities, clinical trial progress, and analyst coverage reflecting market interest.

• In January 2026, Estrella entered into a securities purchase agreement with a healthcare-focused institutional investor involving common stock and warrants offerings [S1].
• In December 2025, the company announced advancement of its STARLIGHT-1 clinical trial into Phase II following a positive Data Safety Monitoring Board recommendation [S9].
• D. Boral Capital initiated coverage of Estrella Immunopharma with a buy recommendation in February 2025 and maintained the buy recommendation in November 2025 [N2][N1].
• Estrella filed a $100 million common stock and warrants offering in December 2024 to support its development activities [N3].
• The company has regained compliance with Nasdaq's minimum bid price requirement as of September 2025 [S3].

The company benefits from a leadership team with deep scientific and industry experience, including a founder with extensive patent holdings in cancer immunotherapy. Progression of the STARLIGHT-1 clinical trial into Phase II following a positive DSMB recommendation indicates advancement in its pipeline. Recent capital raises and securities offerings provide resources to support development activities. Regaining Nasdaq compliance and maintaining governance standards support operational stability. Positive analyst coverage and buy recommendations from D. Boral Capital reflect market interest in the company's potential.

Estrella Immunopharma faces significant liquidity constraints, with a current ratio of 0.12 and cash ratio of 0.1 as of December 31, 2025, and a substantial net loss reported for the fiscal year. The company has experienced Nasdaq compliance issues related to shareholder meetings, which may pose governance risks. As an emerging growth biopharmaceutical company, it is subject to clinical, regulatory, and financing risks inherent in drug development. The absence of disclosed revenue and ongoing net losses highlight the early-stage nature and financial challenges. Dependence on successful clinical trial outcomes and capital raises presents execution risk.

Estrella Immunopharma's moat is primarily based on its proprietary cancer immunotherapy drug candidates and the scientific expertise of its leadership and advisory board. The company's founder and CEO, Dr. Cheng Liu, holds numerous patents and has a track record of developing first-in-class clinical-stage cancer drugs. The specialized focus on novel immunotherapies targeting specific tumor markers and the ongoing clinical development provide potential differentiation. However, as an emerging growth biopharmaceutical company, the moat is contingent on successful clinical and regulatory progress and the ability to secure sufficient capital.

• Liquidity Risk: The company reported a low current ratio of 0.12 and cash ratio of 0.1 as of December 31, 2025, indicating limited short-term liquidity to meet obligations.
• Nasdaq Compliance Risk: Estrella has not held an annual shareholder meeting within the required timeframe, resulting in Nasdaq non-compliance notifications and the need to submit a compliance plan.
• Clinical Development Risk: The success of the company's drug candidates, including EB103 in the STARLIGHT-1 trial, is subject to clinical trial outcomes and regulatory approvals.
• Financial Losses and Capital Needs: The company reported a net loss of approximately $13 million for fiscal 2025 and relies on capital raises such as stock and warrants offerings to fund operations.
• Execution and Market Risks: As an emerging growth biopharmaceutical company, Estrella faces risks related to competition, market acceptance, and the ability to execute its business plan effectively.

• Estrella Immunopharma, Inc. is a Delaware corporation headquartered in Emeryville, California.
• The company is listed on The Nasdaq Stock Market under ticker ESLA, with warrants trading under ESLAW.
• Estrella is classified as an emerging growth company.
• The company is engaged in biopharmaceutical development, focusing on cancer immunotherapy and related treatments.
• Dr. Cheng Liu is the Chief Executive Officer, President, and a director; he has over 20 years of experience in antibody drug discovery and holds over 500 patents related to cancer immunotherapy.
• Peter Xu serves as Chief Financial Officer with extensive investment and management experience.
• The Board of Directors consists of seven members with diverse expertise in finance, medicine, technology, and corporate governance.
• Estrella has an audit committee, compensation committee, and nominating and corporate governance committee, with members meeting Nasdaq independence requirements.
• The company completed a securities purchase agreement in January 2026 involving common stock and warrants offerings.
• Estrella filed a $100 million common stock and warrants offering in December 2024.
• The company is conducting the STARLIGHT-1 Phase I/II clinical trial of its product EB103, advancing into Phase II following a positive Data Safety Monitoring Board recommendation.
• As of December 31, 2025, Estrella had cash and cash equivalents of approximately $1.38 million and current assets of about $1.68 million, with current liabilities of approximately $13.54 million, resulting in a current ratio of 0.12 and a cash ratio of 0.1.
• The company reported a net loss of approximately $13.06 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.35 per share.
• Estrella has not held an annual meeting of shareholders within the required time period but plans to convene one in April 2026 to regain Nasdaq compliance.
• The company has adopted a Related Party Transactions Policy as of September 29, 2023.
• Executive compensation is administered by the board and compensation committee, aiming to retain and attract skilled executives.
• The company has regained compliance with Nasdaq's minimum bid price requirement as of September 2025.
• Estrella's scientific advisory board includes recognized experts in cancer immunotherapy and related fields.